AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 61 min read$PCVX

GUGGENHIME ANDREW sold $573K of PCVX

GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $57.28 ($57.16–$57.76, $0.57M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUGGENHIME ANDREW
Published Jul 6, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The newest disclosed fact is the same-day open-market sale by the company’s President & CFO, totaling ~$572.8K across two trades.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new operational or financial catalyst in the text.

03

What to watch

The sale is explicitly pre-arranged under Rule 10b5-1, which often reduces the signal-to-noise versus discretionary selling.

Relevance 4/10Novelty 3/10Timing: Filed same day as the insider sale (2026-07-06).

Background

The article is a SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

Vaxcyte’s President & CFO Andrew Guggenheim sold about 10,000 shares in open-market transactions on 2026-07-06 at ~$57.16–$57.76.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement and no accompanying company-specific news (earnings, guidance, trials, deals).

Market effects

Sector

No clear sector read-through; this is company-specific insider liquidity activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as reduced confidence by some traders.

Key entities

  • issuer
    Vaxcyte, Inc.

    Subject of the Form 4 insider sale by its President & CFO.

  • insider
    Andrew Guggenheim

    President and CFO who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min